FLEXTRADE-SYSTEMS
FlexTrade Systems, a global leader in multi-asset execution and order management systems, today announced the launch of machine-learning driven real-time market impact analytics, which are now available within FlexTRADER EMS.
This analytics enhancement comes as the industry calls for solutions providers to increase innovation and deliver actionable analytics to help improve decision-making and reduce market impact on the buy-side trading desk. FlexTrade's in-house data science team has driven the new initiative and refined it further through input and collaboration with clients.
FlexTrade's market impact analytics are generated by applying a proprietary neural network model to a large corpus of order data to help investment managers understand the performance of their execution strategies. The solution allows traders to see an estimate of their current and realized market impact in real-time, meaning strategies can be monitored and adjusted automatically based on market conditions. Traders using the solution can also leverage data visualization to understand how the market impact has changed over the life of the order, including any increases or decreases as more volume is traded or when an order is finished or paused. Further, the new offering, deeply integrated directly within the FlexTRADER EMS order blotter, can be viewed holistically alongside third-party analytics to deliver increased transparency, improved trading decision-making and assist with best execution obligations.
FlexTrade's real-time machine-learning driven market impact analytics are available immediately for deployment, with the first client, an EMEA based Tier 1 buy-side asset manager, live in production. FlexTrade will showcase the new analytics offering this month at WBR's TradeTech Europe in Paris on the 11th and 12th of May.
Andy Mahoney, Managing Director, EMEA at FlexTrade, noted : "Designing and delivering ground-breaking innovation is at the core of what we do at FlexTrade. Leveraging new technologies such as machine learning ensures FlexTrade's clients can take advantage of unique, actionable insights to drive their trading in real-time. At a time when the industry is calling for innovation to return following a lull, understandably, caused by the pandemic, we are at the front of the pack offering disruptive technologies led initiatives - rapidly delivered to the market and our clients - that add real tangible value to their execution strategies."
About FlexTrade
Founded in 1996, FlexTrade Systems is the global leader in high performance execution management and order management systems for equities, foreign exchange, options, futures, and fixed income.
A pioneer in the field, FlexTrade is internationally recognized for introducing FlexTRADER, the world's first broker-neutral, and execution management trading system, which allows clients to completely control and customize their proprietary algorithms while maintaining the confidentiality of their trading strategies.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220510006410/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
4Moving Biotech Receives FDA IND Clearance for 4P004, Strengthening Its Position as a Leading Innovator in Disease-Modifying Osteoarthritis Therapeutics8.1.2026 07:30:00 CET | Press release
FDA IND clearance enabling the worldwide expansion of the INFLAM MOTION Phase 2a trial, involving major U.S. sites Advancing the first clinical proof of concept in OA with a first-in-class intra-articular GLP-1 agonist A holistic clinical strategy design establishing the foundation for a future accelerated approval pathway 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for 4P004, enabling the expansion of the Phase 2a INFLAM MOTION clinical trial into the United States (US). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107798042/en/ 4Moving Biotech (4MB), a clinical stage biotechnology company developing next-generation, disease-modifying therapies for osteoarthritis (OA), today announced that the U.S. F
Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo®in France, Denmark, Iceland, Sweden, Finland and Norway8.1.2026 07:30:00 CET | Press release
The agreement builds on Organon’s cardiovascular disease portfolio, leveraging expertise to expand access to new treatments for patients with dyslipidemia, especially statin-intolerant patients.This collaboration addresses a critical gap in care that disproportionately affects women, who are at a 47% higher risk of developing statin intolerance compared to men.i Organon today announced that it has entered into an agreement with Daiichi Sankyo Europe to commercialize Nilemdo® (bempedoic acid) in France, Denmark, Iceland, Sweden, Finland and Norway. Nilemdo® is a new, first-in-class drug indicated for patients with high cholesterol and cardiovascular disease risk. It provides an alternative treatment for patients that cannot be treated effectively with statins.ii “This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo® to patients in France, Denmark, Iceland, Sweden, Finland and Norway,” says Thibault Crosnie
Prodapt Earns ISO 42001 Certification, the New Global Benchmark for Responsible Enterprise AI8.1.2026 07:00:00 CET | Press release
Prodapt today announced that it has been awarded the ISO 42001 certification, the world’s first and the only global standard for AI Management Systems (AIMS). Marking a significant milestone in its journey, Prodapt is setting a higher benchmark to deliver secure, ethical, and scalable AI for global enterprises. ISO 42001 lays a rigorous framework for governing AI across strategy, technology, and operations. The certification, awarded by an independent accredited body, validates Prodapt’s enterprise-grade AI management framework, including executive-led oversight, strong technology foundations, and disciplined operational processes. These measures ensure AI systems are responsibly designed, deployed, monitored, and evolved throughout their lifecycle. The evaluation emphasizes risk management, ethical AI practices, transparency, and scalability, confirming Prodapt’s ability to proactively identify and mitigate risks while ensuring accountability in AI-driven outcomes. Human-in-the-loop c
Azafaros to Present at J.P. Morgan’s 44th Annual Healthcare Conference8.1.2026 07:00:00 CET | Press release
Azafaros, a company building a portfolio to become a leader in lysosomal storage disorders with the goal of addressing neurological symptoms, today announced that it will present at J.P. Morgan’s 44th Annual Healthcare Conference on Thursday, January 15. The company’s presentation will begin at 9:30 am PT/12:30 am ET/6:30 am CET. The presentation will focus on the company’s lead product, nizubaglustat, a potential treatment for rare lysosomal storage disorders with neurological involvement including GM1/GM2 gangliosidoses and Niemann-Pick type C disease ((NPC). Two pivotal Phase 3 studies investigating nizubaglustat in GM1/GM2 gangliosidoses and NPC are currently enrolling, with data expected in 2027. The studies build on positive data from a robust clinical program including the Phase 2 RAINBOW study and the PRONTO natural history study. The Phase 3 studies are financed following the company’s successful completion of €132 million series B round completed in 1H 2025. About nizubaglust
Zilch to Acquire Fjord Bank to Kickstart European Expansion8.1.2026 01:40:00 CET | Press release
Acquisition will provide Zilch, the UK and EMEA’s fastest-growing fintech unicorn, with a European banking licence as it eyes international rollout Zilch, the consumer payments platform powering the future of commerce, today announces it has signed an agreement to acquire AB Fjord Bank, a Lithuania-based bank with approx. $120M in total assets that is authorised and regulated by the Bank of Lithuania and the European Central Bank. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107714872/en/ Zilch to Acquire Fjord Bank to Kickstart European Expansion The acquisition will represent a major strategic milestone for Zilch, providing a European banking licence that will enable the accelerated rollout of its offering across Europe. Zilch will purchase 100% of Fjord Bank and will establish Lithuania as its European headquarters as a consequence of the transaction, using Vilnius as its operational and regulatory platform for expan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom